← Back
Data updated: Jun 28, 2026
ADAMIS PHARMS CORP
Pharma Pharmaceuticals
ADAMIS PHARMS CORP is a pharmaceutical company with 1 FDA-approved products.
2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
ADAMIS PHARMS CORP's Key Drugs
ADAMIS PHARMS CORP's core commercial portfolio centers on SYMJEPI — its most strategically important drugs approved in the last 15 years.
ADAMIS PHARMS CORP's Recent FDA Approvals
New NDA/BLA approvals for ADAMIS PHARMS CORP over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ADAMIS PHARMS CORP's Therapeutic Areas
Disease areas where ADAMIS PHARMS CORP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ADAMIS PHARMS CORP Pipeline Snapshot
Active clinical trials for ADAMIS PHARMS CORP across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SYMJEPI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-06-15
- Latest
- 2021-06-29
- Applications
- 1